Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

NCT01804465 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: SipT Treatment
DRUG: Ipilimumab

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]
[object Object]